Janux Therapeutics Income Statement (2020-2026) | JANX

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
41.17M23.53M41.39M41.50M41.55M41.62M41.80M41.87M46.15M46.25M51.84M52.16M52.34M59.06M59.17M59.30M60.12M60.38M60.87M61.14M
Revenue & cost
Revenue (Quarter)
1.16M1.62M1.59M2.37M1.81M2.85M2.05M1.06M2.52M2.46M1.25M8.90M0.44M10.00M3.73M10.27M
Operating items
Research & Development (Quarter)
8.41M11.17M10.18M14.09M13.74M15.43M15.87M14.92M11.89M12.24M14.07M14.90M18.61M20.81M25.05M34.66M34.63M31.55M26.81M30.99M
Selling, General & Administrative (Quarter)
3.66M3.94M4.95M5.54M6.10M5.68M6.46M6.88M6.44M6.36M7.34M7.82M17.67M8.22M9.84M10.45M10.62M10.85M11.13M10.96M
Operating Expenses (Quarter)
12.06M15.11M15.13M19.63M19.84M21.11M22.33M21.80M18.33M18.60M21.41M22.72M36.28M29.02M34.90M45.12M45.25M42.40M37.95M41.96M
Operating Income (Quarter)
-10.90M-13.49M-13.54M-17.26M-18.02M-18.27M-20.28M-20.75M-15.81M-16.14M-20.16M-13.82M-35.84M-29.02M-34.90M-45.12M-35.25M-42.40M-34.21M-31.69M
EBIT (Quarter)
-10.90M-13.49M-13.54M-17.26M-18.02M-18.27M-20.28M-20.75M-15.81M-16.14M-20.16M-13.82M-35.84M-29.02M-34.90M-45.12M-35.25M-42.40M-34.21M-31.69M
Non-operating items
Interest & Investment Income (Quarter)
0.14M0.07M0.13M0.37M1.33M2.20M2.82M3.24M4.25M4.38M5.40M7.86M7.78M8.81M11.39M11.26M10.94M10.46M9.85M9.72M
Non Operating Income (Quarter)
0.14M0.07M0.13M0.37M1.33M2.20M2.82M3.24M4.25M4.38M5.40M7.86M7.78M8.81M11.39M11.26M10.94M10.46M9.85M9.72M
Net income details
EBT (Quarter)
-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M-60.55M
Profit After Tax (Quarter)
-10.77M-13.71M-13.41M-16.89M-16.70M-15.32M-17.46M-17.83M-11.68M-12.12M-15.95M-7.05M-28.06M-20.22M-23.51M-33.87M-24.31M-34.34M-24.36M-24.85M
Income from Continuing Operations (Quarter)
-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M-60.55M
Consolidated Net Income (Quarter)
-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M-60.55M
Income towards Parent Company (Quarter)
-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M-60.55M
Net Income towards Common Stockholders (Quarter)
-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M-60.55M
Additional items
EPS (Basic) (Quarter)
-2.03-0.57-1.17-1.32-1.31-0.40-1.31-1.29-0.58-0.27-5.47-5.38-6.25-0.38-2.50-2.14-2.11-0.52-0.84-0.96
EPS (Diluted) (Quarter)
-2.03-0.57-1.17-1.32-1.31-0.40-1.31-1.29-0.58-0.27-5.47-5.38-6.25-0.38-2.50-2.14-2.11-0.52-0.84-0.96
Shares Outstanding (Quarter)
41.13M23.53M41.32M41.45M41.53M41.47M41.76M41.84M45.71M44.02M49.05M54.45M54.63M53.75M61.79M61.90M62.02M61.97M62.67M62.94M
Shares Outstanding (Diluted) (Quarter)
41.13M23.53M41.32M41.45M41.53M41.47M41.76M41.84M45.71M44.02M49.05M54.45M54.63M53.75M61.79M61.90M62.02M61.97M62.67M62.94M
EBITDA (Quarter)
-10.90M-13.49M-13.54M-17.26M-18.02M-18.27M-20.28M-20.75M-15.81M-16.14M-20.16M-13.82M-35.84M-29.02M-34.90M-45.12M-35.25M-42.40M-34.21M-31.69M
Interest Expenses (Quarter)
72.67M35.02M37.79M37.72M0.34M37.43M36.61M15.08M253.76M286.88M313.49M131.17M98.68M106.84M28.50M38.57M